Alpine Immune Sciences Inc.

Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu

Entering 2025, biopharma industry observers expected an uptick of merger-and-acquisition activity, coming off a 2024 that saw some historic lows for such activity. Hopes were raised with some sizeab

The past year yielded a downward trend across the board for dealmaking in the biopharmaceutical sector, regardless of which metric one looks at. In the area of mergers and acquisitions, deal volume, t

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported